Prostate-specific membrane antigen PSM (35-40), human – Other Categories

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein found in all prostate tissue- androgen levels negatively regulate its expression. PSMA expression correlates with cancer aggressiveness and represents an independent indicator of poor disease outcomes. PSMA is being explored as a clinical biomarker to allow differentiation of aggressive prostate cancers from other cases using imaging and RT-PCR. The epitope PSMA (35-40) is from the splice isoform PSMA-1. There has been progress in generating PSMA targeting radioligands as a therapy for various cancers. θ and β radiation probes such as 177Lu-PSMA-617 have been developed and shown in trials to be clinically effective treatments against metastatic prostate cancer. Other studies have tested the PSMA targeting radioligands efficacy against triple-negative breast cancer cells. Further work with the PSMA (35-40) epitope could help progress the outlook for these aggressive cancers.

Technical specification

Price